Krystal Biotech (NASDAQ:KRYS) Now Covered by The Goldman Sachs Group

Investment analysts at The Goldman Sachs Group assumed coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a research note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $441.00 price target on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 27.52% from the stock’s current price.

KRYS has been the subject of several other research reports. TD Cowen raised their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Weiss Ratings cut Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Citigroup raised their price objective on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada started coverage on shares of Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $377.20.

Krystal Biotech Stock Up 0.2%

NASDAQ:KRYS traded up $0.86 on Thursday, hitting $345.82. The stock had a trading volume of 199,945 shares, compared to its average volume of 331,980. The company has a fifty day moving average price of $343.40 and a two-hundred day moving average price of $315.19. Krystal Biotech has a 1-year low of $159.24 and a 1-year high of $382.54. The stock has a market cap of $10.24 billion, a price-to-earnings ratio of 43.34 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, analysts anticipate that Krystal Biotech will post 7.48 earnings per share for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 13.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the stock. QRG Capital Management Inc. grew its position in shares of Krystal Biotech by 17.2% during the second quarter. QRG Capital Management Inc. now owns 1,501 shares of the company’s stock worth $558,000 after buying an additional 220 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Krystal Biotech during the 2nd quarter worth approximately $46,000. Allworth Financial LP increased its position in shares of Krystal Biotech by 877.1% in the 2nd quarter. Allworth Financial LP now owns 469 shares of the company’s stock valued at $174,000 after purchasing an additional 421 shares during the last quarter. Nykredit A S acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at $438,000. Finally, Corient Private Wealth LP raised its holdings in shares of Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock valued at $11,357,000 after purchasing an additional 27,035 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.